

Contraception Requirements (HRPP 3.9)

Description:

This policy describes the contraception requirements for subjects participating in research.

Pregnancy and Lactation Labeling Available:

For drugs/biologics for which pregnancy and lactation labeling is available, the ICFs must include the appropriate standard contraception language based on the following categories:

- **Group 1 Drugs** (*no systemic absorption of the drug/biologic*)
 - The protocol may NOT require use of contraception. Exceptions must be approved by the IRB.
- **Group 2 Drugs** (*human data shows no evidence of adverse developmental outcomes*)
 - The protocol may require ONE form of contraception with IRB approval.
- **Group 3 Drugs** (*animal studies show no evidence of adverse developmental outcomes*)
 - The protocol may require ONE form of contraception with IRB approval.
- **Group 4 Drugs** (*animal studies show evidence of adverse developmental outcomes, at dose levels higher than those to be used in the study*)
 - The protocol MUST require ONE or TWO form(s) of contraception with IRB approval.
- **Group 5 Drugs** (*animal or human studies show evidence of adverse developmental outcomes, or drug mechanism of action suggests the possibility of adverse developmental outcomes*)
 - The protocol MUST require TWO forms of concurrent contraception.

Pregnancy and Lactation Labeling NOT Available:

For drugs/biologics for which pregnancy and lactation labeling is not available, the ICFs must include the appropriate standard contraception language based upon the following categories:

- **Category A Drugs** (*controlled studies show no risk to fetus*)
 - The protocol may NOT require use of contraception. Exceptions must be approved by the IRB.
- **Category B Drugs** (*no evidence of risk to fetus in humans*)
 - The protocol may require the use of ONE form of contraception with IRB approval.
- **Category C Drugs** (*risk to fetus cannot be ruled out*)

- The protocol MUST require use of ONE or TWO form(s) of concurrent contraception.
- **Category D Drugs** (*positive evidence of risk to fetus*)
 - The protocol MUST require TWO forms of concurrent contraception.
- **Category X Drugs** (*indicates should NOT be used if pregnant*)
 - The protocol MUST require TWO forms of concurrent contraception.

General Considerations:

The duration of contraception must be stated in the IRB application and ICF. If it's required for longer than the time the drug is being administered, justification must be provided.

[CLICK HERE](#) - Addendum #1 lists ICF standard language pregnancy risk statements.

The ICF must include standard contraception language except:

- Group 5 drugs
- Category D drugs
- Category X drugs

If a sponsor mandates specific contraception language, this may be used in lieu provided the IRB determines it's acceptable.